Wockhardt’s Zaynich® (Zidebactam/Cefepime, WCK 5222) achieves highest – ever efficacy meeting superiority in a global, pivotal, registration – enabling Phase III study in complicated urinary tract infection (cUTI) achieving 96.8% clinical cure rate